LD2-3
LD2-3 is a topoisomerase I inhibitor. LD2-3 can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. LD2-3 can be coupled with CEA antibodies to form ADC drugs for the study of CEA overexpressing tumors[1].
Product Specifications
CAS Number
[3040077-52-6]
UNSPSC
12352005
Target
ADC Payload; Topoisomerase
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C(C=CC1=O)N1CC(NCCC(N[C@@H](CCC(NC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)CC(N)=O)=O)C(N[C@@H](C(C)C)C(N[C@@H](C)C(NCOCC(C)(C)C(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O)=O
Molecular Formula
C59H74FN11O18
Molecular Weight
1244.28
References & Citations
[1]Charng-Sheng TSAI, et al. Anti-CEA antibody drug conjugates and methods of use. WO2024110905.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Topo I
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
